Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-102 in Healthy Subjects and Chronic Hepatitis B
NCT06744686Phase 1Completed
- Sponsor
- Hepatera
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HT-102 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Hepatera. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at 8 weeks and Time to Reach Maximum Plasma Concentration at 8 weeks. Started Jun 2023; status: completed.
02
Drugs
HT-102
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06744686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744686.